Xiangyu Gao - Publications

Development and dissemination of precision medicine approaches in gastric cancer management

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Published: October 24, 2025

Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: March 27, 2025

Enhanced integrated therapy for breast cancer employing Honokiol-loaded mesoporous polydopamine nanoparticles in conjunction with photothermal effects and low-dose metformin.

Journal: APL bioengineering

Published: January 06, 2025

Identifying potential beneficiaries of neoadjuvant therapy in borrmann type III and IV gastric cancer: A treatment heterogeneity analysis using causal survival forests.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 06, 2025

First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.

Journal: Nature medicine

Published: September 29, 2024

Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 31, 2024

CD24-Targeted NIR-II Fluorescence Imaging Enables Early Detection of Colorectal Neoplasia.

Journal: Cancer research

Published: January 02, 2024

Kinase D-interacting Substrate of 220 kDa Is Overexpressed in Gastric Cancer and Associated With Local Invasion.

Journal: Cancer genomics & proteomics

Published: August 17, 2023

Associations of subcutaneous fat area and Systemic Immune-inflammation Index with survival in patients with advanced gastric cancer receiving dual PD-1 and HER2 blockade.

Journal: Journal for immunotherapy of cancer

Published: May 26, 2023

One-Minute Iodine Isotope Labeling Technology Enables Noninvasive Tracking and Quantification of Extracellular Vesicles in Tumor Lesions and Intact Animals.

Journal: Molecular pharmaceutics

Published: May 22, 2023

Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.

Journal: The Lancet. Oncology

Published: May 18, 2023

Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.

Journal: Nature medicine

Published: May 15, 2023